Log in

Relevant bibliographies by topics / Pharmaceutical policy / Journal articles

To see the other types of publications on this topic, follow the link: Pharmaceutical policy.

Journal articles on the topic 'Pharmaceutical policy'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pharmaceutical policy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Alajärvi, Lasse, Johanna Timonen, Piia Lavikainen, and Janne Martikainen. "Attitudes and Considerations towards Pharmaceuticals-Related Environmental Issues among Finnish Population." Sustainability 13, no. 22 (2021): 12930. http://dx.doi.org/10.3390/su132212930.

Full text

Abstract:

A number of policy recommendations identify the general public as a key participant in environmentally sustainable pharmaceutical policies. However, research into pharmaceuticals-related environmental issues from the population perspective is scarce. We studied the awareness among Finnish adults (n = 2030) of pharmaceutical residues in Finnish waterways, their perceived environmental sources, views on pharmaceuticals-related environmental issues, and their association with background characteristics. Of the respondents, 89.5% were aware of the presence of pharmaceuticals in Finnish waterways.

APA, Harvard, Vancouver, ISO, and other styles

2

Iyengar, Renganthan. "PHARMACEUTICAL PRICING POLICY AND CONTROL– INDIAN PERSPECTIVE." Asian Journal of Pharmaceutical and Clinical Research 9, no. 6 (2016): 305. http://dx.doi.org/10.22159/ajpcr.2016.v9i6.14461.

Full text

Abstract:

ABSTRACTPharmaceutical sector is playing a vital role towards the wellness of the people and economic development of India. The innovation, development, production and marketing of medicines are accountable to pharmaceutical industry. Drugs and pharmaceuticals, healthcare delivery, medical devices among others come under the purview of healthcare sector. It is the duty of the Government to ensure the availability of the lifesaving drugs at reasonable prices by means of considering the interest of both the producers and the buyers. In order to safeguard the public health, National Pharmaceutica

APA, Harvard, Vancouver, ISO, and other styles

3

Probyn, Andrew J. "Some drugs more equal than others: pseudo-generics and commercial practice." Australian Health Review 28, no. 2 (2004): 207. http://dx.doi.org/10.1071/ah040207.

Full text

Abstract:

This article analyses the impact of the Department of Health and Ageing?s brand price premium policy for some products listed on the Pharmaceutical Benefits Scheme. The policy, introduced in 1990, allows pharmaceutical companies to charge patients an out-of-pocket expense for post-patent brands of pharmaceuticals. One of the policy?s intended goals was to increase consumer awareness of price differentials between competing brands, with a view to encouraging greater use of cheaper generic products. More than fourteen years since its introduction, it is debatable whether the policy has achieved

APA, Harvard, Vancouver, ISO, and other styles

4

Weiss, Lawrence D., and Stuart O. Schweitzer. "Pharmaceutical Economics and Policy." Journal of Public Health Policy 19, no. 3 (1998): 379. http://dx.doi.org/10.2307/3343547.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mullins, C. Daniel. "Pharmaceutical prices and policy." Clinical Therapeutics 26, no. 8 (2004): 1326. http://dx.doi.org/10.1016/s0149-2918(04)80193-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sun, Qiang, Michael A. Santoro, Qingyue Meng, Caitlin Liu, and Karen Eggleston. "Pharmaceutical Policy In China." Health Affairs 27, no. 4 (2008): 1042–50. http://dx.doi.org/10.1377/hlthaff.27.4.1042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Garattini, Livio, and Dante Cornago. "Pharmaceutical policy in Italy." European Journal of Health Economics 7, no. 2 (2006): 89–90. http://dx.doi.org/10.1007/s10198-006-0353-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

CONTRACTOR, SUNIL H., PIYUSH KUMAR, and THOMAS W. LEIGH. "THE IMPACT OF GOVERNANCE MECHANISMS ON ESCALATION OF COMMITMENT." International Journal of Innovation Management 16, no. 04 (2012): 1250023. http://dx.doi.org/10.1142/s1363919612500235.

Full text

Abstract:

There are conflicting opinions on whether the existing US legal and economic environment for pharmaceutical research is conducive for the repurposing of patent-protected drugs. This article therefore addresses the following innovation policy questions: Does US patent law and regulatory policy assign sufficient value to new use patents in the pharmaceutical industry? If present law and regulatory policy does assign sufficient value, what evidence is there that the pharmaceutical industry is actively involved in technology strategies to repurpose existing pharmaceuticals? Based on an evaluation

APA, Harvard, Vancouver, ISO, and other styles

9

ROEMER-MAHLER, ANNE. "The rise of companies from emerging markets in global health governance: Opportunities and challenges." Review of International Studies 40, no. 5 (2014): 897–918. http://dx.doi.org/10.1017/s0260210514000345.

Full text

Abstract:

AbstractThe article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies. In so doing, pharmaceutical companies from emerging markets have facilitated the implementation of a key goal of global health policy: widening access to pharmaceutical treatment and prevention. Yet, looking closer at the political economy underlying their involvement, the article exposes a tension between this policy goal and the political economy o

APA, Harvard, Vancouver, ISO, and other styles

10

Gautam, Tara Prashad. "HRM Practices and its Impact on Customers’ Satisfaction of Pharmaceutical Companies in Nepal." Nepal Journal of Multidisciplinary Research 4, no. 4 (2021): 63–69. http://dx.doi.org/10.3126/njmr.v4i4.43210.

Full text

Abstract:

This paper aims to investigate the HRM practices and impact on Customers satisfaction in the pharmaceutical companies of Nepal A structured questionnaire was developed and distributed among 386 employees of 37 pharmaceuticals companies. Statistical correlation analysis was used to assess the impact of HRM practices on Customer satisfaction. The study reveals that employees in pharmaceutical companies are satisfied with the recruitment and selection, and training and development policy and practices of pharmaceutical companies. On the other hand, employees are dissatisfied with the human resour

APA, Harvard, Vancouver, ISO, and other styles

11

Salikhova, Olena, and Daria Honcharenko. "Policy of endogenous development of pharmaceuticals in China: lessons for Ukraine." Economy and forecasting 2020, no. 2 (2020): 105–19. http://dx.doi.org/10.15407/econforecast2020.02.105.

Full text

Abstract:

This article provides overview of the programs and plans, tools of scientific and technological, innovation and industry policies for new drug discovery. The authors substantiate that China has a government-led integrated approach to protecting and strengthening pharmaceutical sector. Discovered and proved the fact that the Chinese Government is encouraging R&D in the pharmaceutical sector, with special attention to the biotechnologies and is providing substantial support in the form of subsidies, tax incentives and establishment of special high-tech zones to encourage the production of ne

APA, Harvard, Vancouver, ISO, and other styles

12

Nasir, Fazli. "Welcome to Pharmaceutical Communications." Pharmaceutical Communications 1, no. 01 (2022): 01. http://dx.doi.org/10.55627/pharma.001.001.0203.

Full text

Abstract:

Welcome to the inaugural issue of Pharmaceutical Communications-a biannual, open access, and peer-reviewed journal aiming to publish high-quality research articles in the field of basic & advanced pharmaceutics and pharmaceutical technology. Pharmaceutical Communications is a biannual, peer-reviewed journal published online and in print that primarily publishes research articles and reviews that focus on basic and advanced pharmaceutics. The journal accepts manuscripts related to but not limited to, the processing of pharmaceuticals, such as crystallization, lyophilization, chemical stabil

APA, Harvard, Vancouver, ISO, and other styles

13

Jorgensen, Paul D. "Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda." Journal of Law, Medicine & Ethics 41, no. 3 (2013): 561–70. http://dx.doi.org/10.1111/jlme.12065.

Full text

Abstract:

The point, for the 946,326th time is that people get elected to office by currying the favor of powerful interest groups. They don’t get elected for their excellence as political philosophers.Congress has consistently failed to solve some serious problems with the cost, effectiveness, and safety of pharmaceuticals. In part, this failure results from the pharmaceutical industry convincing legislators to define policy problems in ways that protect industry profits. By targeting campaign contributions to influential legislators and by providing them with selective information, the industry manage

APA, Harvard, Vancouver, ISO, and other styles

14

Stang, Paul. "Handbook of Pharmaceutical Public Policy." Drug Information Journal 42, no. 1 (2008): 65–66. http://dx.doi.org/10.1177/009286150804200110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

ROVIRA, J. "Economic analysis and pharmaceutical policy." Anaesthesia 50, s10 (1995): 49–51. http://dx.doi.org/10.1111/j.1365-2044.1995.tb06191.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kakihara, Hiroaki, Yoko Ibuka, and Xinxin Ma. "Pharmaceutical policy and health economics." Folia Pharmacologica Japonica 141, no. 2 (2013): 95–99. http://dx.doi.org/10.1254/fpj.141.95.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 21, no. 2 (1999): 382. http://dx.doi.org/10.1016/s0149-2918(00)88294-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Sclar, DavidAlexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 18, no. 3 (1996): 520. http://dx.doi.org/10.1016/s0149-2918(96)80033-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Sclar, DavidAlexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 18, no. 5 (1996): 876. http://dx.doi.org/10.1016/s0149-2918(96)80047-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 18, no. 6 (1996): 1226. http://dx.doi.org/10.1016/s0149-2918(96)80077-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Alexander Sclar, David. "Pharmaceutical economics & health policy." Clinical Therapeutics 18, no. 4 (1996): 702. http://dx.doi.org/10.1016/s0149-2918(96)80220-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 19, no. 6 (1997): 1424–25. http://dx.doi.org/10.1016/s0149-2918(97)80015-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 19, no. 5 (1997): 1068–69. http://dx.doi.org/10.1016/s0149-2918(97)80059-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sclar, D. "Pharmaceutical economics & health policy." Clinical Therapeutics 19, no. 1 (1997): 84–85. http://dx.doi.org/10.1016/s0149-2918(97)80075-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 19, no. 4 (1997): 760–61. http://dx.doi.org/10.1016/s0149-2918(97)80099-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 19, no. 2 (1997): 314–15. http://dx.doi.org/10.1016/s0149-2918(97)80119-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 19, no. 3 (1997): 538–39. http://dx.doi.org/10.1016/s0149-2918(97)80138-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 20, no. 1 (1998): 158–59. http://dx.doi.org/10.1016/s0149-2918(98)80042-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 20, no. 3 (1998): 550–51. http://dx.doi.org/10.1016/s0149-2918(98)80064-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 20, no. 5 (1998): 992. http://dx.doi.org/10.1016/s0149-2918(98)80080-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 20, no. 2 (1998): 326–27. http://dx.doi.org/10.1016/s0149-2918(98)80095-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 20, no. 6 (1998): 1192–93. http://dx.doi.org/10.1016/s0149-2918(98)80114-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sclar, David Alexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 20, no. 4 (1998): 762–63. http://dx.doi.org/10.1016/s0149-2918(98)80138-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Field, Robert I. "Handbook of Pharmaceutical Public Policy." Journal of Legal Medicine 29, no. 2 (2008): 255–62. http://dx.doi.org/10.1080/01947640802080546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kay, Adrian. "Pharmaceutical Policy in the UK." Public Money and Management 21, no. 4 (2001): 51–54. http://dx.doi.org/10.1111/1467-9302.00285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

REICH, MICHAEL R. "Bangladesh pharmaceutical policy and politics." Health Policy and Planning 9, no. 2 (1994): 130–43. http://dx.doi.org/10.1093/heapol/9.2.130.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Alexander Sclar, David. "Pharmaceutical economics & health policy." Clinical Therapeutics 17, no. 1 (1995): 88. http://dx.doi.org/10.1016/0149-2918(95)80010-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Sclar, DavidAlexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 17, no. 4 (1995): 748. http://dx.doi.org/10.1016/0149-2918(95)80051-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sclar, DavidAlexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 17, no. 6 (1995): 1158. http://dx.doi.org/10.1016/0149-2918(95)80094-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Sclar, DavidAlexander. "Pharmaceutical economics & health policy." Clinical Therapeutics 17, no. 3 (1995): 516. http://dx.doi.org/10.1016/0149-2918(95)80116-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Traulsen, Janine Morgall, and Anna Birna Almarsdóttir. "The argument for pharmaceutical policy." Pharmacy World & Science 27, no. 1 (2005): 7–12. http://dx.doi.org/10.1007/s11096-004-5151-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Salikhova, Olena, and Daria Honcharenko. "Challenges of the COVID-19 pandemic to pharmaceutical manufacturing: the EU and Ukraine’s response." Economy and forecasting 2021, no. 3 (2021): 88–113. http://dx.doi.org/10.15407/econforecast2021.03.088.

Full text

Abstract:

The global COVID-19 pandemic, which has caused a shortage of medicines and medical products, as well as pharmaceutical products, especially active pharmaceutical ingredients, has demonstrated Ukraine’s unpreparedness to face such challenges and threats. This encourages the search for effective mechanisms to reduce vulnerability, ensure stability and develop pharmaceutical activities. The purpose of the article is to draw on the experience of the European Union to justify the need to introduce measures of the policy of stimulating the development of pharmaceuticals in Ukraine in order to reduce

APA, Harvard, Vancouver, ISO, and other styles

43

Salikhova, Olena, and Daria Honcharenko. "Challenges of the COVID-19 pandemic to pharmaceutical manufacturing: the EU and Ukraine’s response." Ekonomìka ì prognozuvannâ 2021, no. 3 (2021): 93–117. http://dx.doi.org/10.15407/eip2021.03.093.

Full text

Abstract:

The global COVID-19 pandemic, which has caused a shortage of medicines and medical products, as well as pharmaceutical products, especially active pharmaceutical ingredients, has demonstrated Ukraine’s unpreparedness to face such challenges and threats. This encourages the search for effective mechanisms to reduce vulnerability, ensure stability and develop pharmaceutical activities. The purpose of the article is to draw on the experience of the European Union to justify the need to introduce measures of the policy of stimulating the development of pharmaceuticals in Ukraine in order to reduce

APA, Harvard, Vancouver, ISO, and other styles

44

CHAQUÉS, LAURA, and ANNA PALAU. "Comparing the Dynamics of Change in Food Safety and Pharmaceutical Policy in Spain." Journal of Public Policy 29, no. 1 (2009): 103–26. http://dx.doi.org/10.1017/s0143814x09000981.

Full text

Abstract:

ABSTRACTComparative analysis shows that while policy windows and policy entrepreneurs are important, they are insufficient to account for policy change. An understanding of the institutional setting is key to explaining the speed and the magnitude of policy dynamics. In both food safety and pharmaceutical policy in Spain, a redefinition of policy image has involved a transformation of the policy subsystem. In the case of food safety such a paradigm shift has represented a dramatic change, in the case of pharmaceuticals it has meant a gradual process that has developed over a decade. Periods of

APA, Harvard, Vancouver, ISO, and other styles

45

Guillén, Ana M., and Laura Cabiedes. "Reforming Pharmaceutical Policies in the European Union: A “Penguin Effect”?" International Journal of Health Services 33, no. 1 (2003): 1–28. http://dx.doi.org/10.2190/1jc6-frl4-qm2l-qn6e.

Full text

Abstract:

Pharmaceutical policies form a substantial part of health care services, from the point of view of both equity and efficiency goals. Expenditure on pharmaceuticals has been growing steadily over the last few decades, and countries are finding the financing of drugs increasingly difficult. This article surveys the changes in pharmaceutical policies in the E.U. countries from the mid-1980s through the 1990s. It focuses primarily on policies dealing with cost control of publicly funded pharmaceuticals. In their analysis of these changes, the authors classify policies (or “packages of measures”),

APA, Harvard, Vancouver, ISO, and other styles

46

Curti, Andrea M. "The WTO Dispute Settlement Understanding: An Unlikely Weapon in the Fight Against AIDS." American Journal of Law & Medicine 27, no. 4 (2001): 469–85. http://dx.doi.org/10.1017/s0098858800008224.

Full text

Abstract:

One of the most controversial aspects of the World Trade Organization (WTO) is its trade policy governing pharmaceutical products that treat AIDS and other diseases. Critics contend that the WTO unreasonably restricts the trade of pharmaceuticals in order to protect the profit margin of western drug producers at the expense of infected populations in developing countries. Supporters of the WTO's trade policy argue that protecting the intellectual property (IP) rights of pharmaceutical products is essential to providing an incentive for further drug research and development.

APA, Harvard, Vancouver, ISO, and other styles

47

Honcharenko, Daria. "PHARMACEUTICAL INDUSTRY DEVELOPMENT: KEY POLICY INSTRUMENTS IN CHINA." EUREKA: Social and Humanities 4 (July 31, 2020): 3–9. http://dx.doi.org/10.21303/2504-5571.2020.001369.

Full text

Abstract:

The article provides an overview of programs, plans, tools of scientific and technological, innovation and industrial policy aimed at creating and producing new drugs in China; it is substantiated that the Chinese government uses an integrated approach in the implementation of mechanisms to protect and strengthen the pharmaceutical industry. It is demonstrated that the Chinese government provides business support in the form of subsidies, tax incentives, the creation of special zones for the development of high-tech industries, and helps to attract foreign direct investment in contract manufac

APA, Harvard, Vancouver, ISO, and other styles

48

Daria, Honcharenko. "PHARMACEUTICAL INDUSTRY DEVELOPMENT: KEY POLICY INSTRUMENTS IN CHINA." EUREKA: Social and Humanities, no. 4 (July 31, 2020): 3–9. https://doi.org/10.21303/2504-5571.2020.001369.

Full text

Abstract:

The article provides an overview of programs, plans, tools of scientific and technological, innovation and industrial policy aimed at creating and producing new drugs in China; it is substantiated that the Chinese government uses an integrated approach in the implementation of mechanisms to protect and strengthen the pharmaceutical industry. It is demonstrated that the Chinese government provides business support in the form of subsidies, tax incentives, the creation of special zones for the development of high-tech industries, and helps to attract foreign direct investment in contract manufac

APA, Harvard, Vancouver, ISO, and other styles

49

Yun, Mikyung. "Government Procurement Defence Under GATT 1994 Article III:8(a): A Critical Review of the Turkey-Pharmaceutical Products Dispute." Journal of World Trade 57, Issue 1 (2023): 183–208. http://dx.doi.org/10.54648/trad2023007.

Full text

Abstract:

This article critically reviews the Turkey-Pharmaceutical Products Dispute, focusing on the question of whether Turkey’s drug insurance reimbursement scheme can be regarded as government procurement, which would allow Turkey’s drug production localization policy to be exempt from national treatment obligation. Both the panel (on the account that there was no ownership by the government) and the arbitrators (on the account that there was insufficient control of pharmaceutical products subject to the dispute), ruled against Turkey’s government procurement defence. In contrast, this article argue

APA, Harvard, Vancouver, ISO, and other styles

50

Doran, Evan, and Jane Robertson. "Australia's pharmaceutical cost sharing policy: reducing waste or affordability?" Australian Health Review 33, no. 2 (2009): 231. http://dx.doi.org/10.1071/ah090231.

Full text

Abstract:

In this paper we argue that Australia?s pharmaceutical cost sharing policy has been applied as if cost sharing is unproblematic for medicine affordability and good health outcomes. Australian and international experience with pharmaceutical cost sharing strongly suggests a negative impact on affordability and quality use of medicines, disproportionately affecting low income patients. We argue that Australia?s use of cost sharing reflects the currency of a cognitively powerful and morally charged idea ? moral hazard. Moral hazard refers to the change in behaviour induced by insurance coverage.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!